Moreover, TGFβ1 may have other therapeutic advantages in fatal infectious diseases such as COVID-19, by inhibiting one of the SARS-CoV-2 attachments and point of entry, like the ACE2 receptor (14–16). This evidence concerns the gene TGFB1 and COVID-19.